{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:39:13Z","timestamp":1793975953284,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES19041ALVA"],"award-info":[{"award-number":["INVES19041ALVA"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019179","name":"Fundaci\u00f3n La Caixa","doi-asserted-by":"publisher","award":["HR21-00083"],"award-info":[{"award-number":["HR21-00083"]}],"id":[{"id":"10.13039\/501100019179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021778","name":"Agencia Nacional de Promoci\u00f3n de la Investigaci\u00f3n, el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PICT 2020-1552"],"award-info":[{"award-number":["PICT 2020-1552"]}],"id":[{"id":"10.13039\/501100021778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015884","name":"Fundaci\u00f3n Olga Torres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RyC 2019-026406-I"],"award-info":[{"award-number":["RyC 2019-026406-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["488\/C\/2019"],"award-info":[{"award-number":["488\/C\/2019"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016120","name":"Gobierno de Navarra Departamento de Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["765394"],"award-info":[{"award-number":["765394"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["945393 - T2EVOLVE"],"award-info":[{"award-number":["945393 - T2EVOLVE"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["MCIN\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PID2020-112892RB-100"],"award-info":[{"award-number":["PID2020-112892RB-100"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PID2020-113174-RA-100"],"award-info":[{"award-number":["PID2020-113174-RA-100"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01128"],"award-info":[{"award-number":["PI19\/01128"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["0011\u20131411-2020-000075"],"award-info":[{"award-number":["0011\u20131411-2020-000075"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.xcrm.2023.100978","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T20:22:54Z","timestamp":1679084574000},"page":"100978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T\u00a0cells for efficacious intratumoral adoptive immunotherapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Irene","family":"Olivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elixabet","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gonzalez-Gomariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hervas-Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina V.","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Luri-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Cirella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josune","family":"Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Glez-Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Garasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Eguren-Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Guedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A.","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.100978_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.100978_bib2","series-title":"Next-Generation CAR T-Cell Therapies","author":"Young","year":"2022"},{"key":"10.1016\/j.xcrm.2023.100978_bib3","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib4","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8\u00a0+ -enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100978_bib5","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus\u2013associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013Reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib7","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus\u2013associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100978_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib9","doi-asserted-by":"crossref","first-page":"e002741","DOI":"10.1136\/jitc-2021-002741","article-title":"CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies","volume":"9","author":"Abdin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.100978_bib10","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell\u2013encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100978_bib12","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T\u00a0cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2023.100978_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.xcrm.2023.100978_bib14","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib15","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201545552","article-title":"Adoptive T-cell therapy for cancer: the era of engineered T\u00a0cells","volume":"45","author":"Bonini","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib16","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T\u00a0cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41423-020-0464-1","article-title":"Engineering bionic T\u00a0cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms","volume":"17","author":"Etxeberria","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib18","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","article-title":"Interleukin-12: biological properties and clinical application","volume":"13","author":"Del Vecchio","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib19","doi-asserted-by":"crossref","first-page":"108189","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2023.100978_bib20","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.100978_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.smim.2013.10.014","article-title":"Interleukin-18, more than a Th1 cytokine","volume":"25","author":"Novick","year":"2013","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib22","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/2326-6066.CIR-19-0910","article-title":"Optimization of T-cell receptor\u2013modified T\u00a0cells for cancer therapy","volume":"8","author":"Drakes","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib24","article-title":"Intratumoral gene transfer of mRNAs encoding interleukin-12 in combination with decoy-resistant interleukin-18 improves local and systemic antitumor immunity","author":"Cirella","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib25","doi-asserted-by":"crossref","first-page":"101908","DOI":"10.1016\/j.jbc.2022.101908","article-title":"Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity","volume":"298","author":"Detry","year":"2022","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2023.100978_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.100978_bib27","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1158\/1078-0432.CCR-13-0568","article-title":"The IL-18 antagonist IL-18\u2013binding protein is produced in the human ovarian cancer microenvironment","volume":"19","author":"Carbotti","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib28","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T\u00a0cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2023.100978_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T\u00a0cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100978_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T\u00a0cell therapy: an ignition key for systemic immunity in solid tumors","volume":"40","author":"Cherkassky","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.100978_bib33","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib34","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.100978_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T\u00a0cells","volume":"198","author":"Overwijk","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in\u00a0vivo antitumor activity of tumor-reactive CD8\u00a0+ T Cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.100978_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8\u03b1\u00a0+ dendritic cells in cytotoxic T\u00a0cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.100978_bib38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100978_bib39","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib40","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1002\/cam4.2583","article-title":"MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers","volume":"8","author":"Peng","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib42","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","article-title":"Enhanced effector responses in activated CD8+ T\u00a0cells deficient in diacylglycerol kinases","volume":"73","author":"Riese","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.1090148","article-title":"Control of effector CD8\u00a0+ T\u00a0cell function by the transcription factor eomesodermin","volume":"302","author":"Pearce","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.100978_bib44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ni1268","article-title":"Effector and memory CD8+ T\u00a0cell fate coupled by T-bet and eomesodermin","volume":"6","author":"Intlekofer","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10409239891204198","article-title":"Concepts and principles of O-linked glycosylation","volume":"33","author":"Van den Steen","year":"1998","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib46","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2005-05-2112","article-title":"CD43 is a ligand for E-selectin on CLA+ human T\u00a0cells","volume":"107","author":"Fuhlbrigge","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2023.100978_bib47","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.4049\/jimmunol.175.12.8042","article-title":"CD43 functions as a ligand for E-selectin on activated T\u00a0cells","volume":"175","author":"Matsumoto","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","article-title":"Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors","volume":"156","author":"Croci","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1083\/jcb.117.4.895","article-title":"The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide","volume":"117","author":"Foxall","year":"1992","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib50","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.151.11.6338","article-title":"Neutrophils roll on E-selectin","volume":"151","author":"Lawrence","year":"1993","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib51","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI116889","article-title":"E-selectin supports neutrophil rolling in\u00a0vitro under conditions of flow","volume":"92","author":"Abbassi","year":"1993","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.100978_bib52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T\u00a0cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib53","doi-asserted-by":"crossref","first-page":"155749","DOI":"10.1016\/j.cyto.2021.155749","article-title":"The role of Th22 cells, from tissue repair to cancer progression","volume":"149","author":"Doulabi","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.xcrm.2023.100978_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T\u00a0cell invigoration and polyclonal T\u00a0cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib56","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1189\/jlb.0705358","article-title":"Interleukin-10 and the immune response against cancer: a counterpoint","volume":"78","author":"Mocellin","year":"2005","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib57","doi-asserted-by":"crossref","first-page":"e1026533","DOI":"10.1080\/2162402X.2015.1026533","article-title":"miR-155 releases the brakes on antitumor T\u00a0cells","volume":"4","author":"Ji","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2023.100978_bib58","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bcp.2011.05.031","article-title":"Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer","volume":"82","author":"Cond\u00e9","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2023.100978_bib59","series-title":"Advances in immunology","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-cell therapy for cancer","author":"Yang","year":"2016"},{"key":"10.1016\/j.xcrm.2023.100978_bib60","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8\u00a0+ T\u00a0cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib61","doi-asserted-by":"crossref","first-page":"e003351","DOI":"10.1136\/jitc-2021-003351","article-title":"Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants","volume":"9","author":"Conde","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.100978_bib62","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-19-4073","article-title":"Interventional radiology for local immunotherapy in oncology","volume":"27","author":"Tselikas","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.semcancer.2022.05.002","article-title":"The IL-1 family in tumorigenesis and antitumor immunity","volume":"86","author":"Sun","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib64","doi-asserted-by":"crossref","first-page":"e000528","DOI":"10.1136\/jitc-2020-000528","article-title":"Cell death induced by cytotoxic CD8\u00a0+ T\u00a0cells is immunogenic and primes caspase-3\u2013dependent spread immunity against endogenous tumor antigens","volume":"8","author":"Jaime-Sanchez","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.100978_bib65","doi-asserted-by":"crossref","first-page":"e000325","DOI":"10.1136\/jitc-2019-000325","article-title":"Cellular cytotoxicity is a form of immunogenic cell death","volume":"8","author":"Minute","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2023.100978_bib66","doi-asserted-by":"crossref","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"S\u00e1nchez-Paulete","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2023.100978_bib67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ni.f.203","article-title":"Protein-glycan interactions in the control of innate and adaptive immune responses","volume":"9","author":"van Kooyk","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41374-018-0124-6","article-title":"T-cell trafficking plays an essential role in tumor immunity","volume":"99","author":"Aires","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.xcrm.2023.100978_bib69","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1102495","article-title":"CD8 T\u00a0cell priming in the presence of IFN-\u03b1 renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T\u00a0cell therapy","volume":"189","author":"Hervas-Stubbs","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib70","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2023.100978_bib71","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1084\/jem.20050003","article-title":"SOCS-1 regulates IL-15\u2013driven homeostatic proliferation of antigen-naive CD8 T\u00a0cells, limiting their autoimmune potential","volume":"202","author":"Davey","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2023.100978_bib72","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2012.12.006","article-title":"MicroRNA-155 is required for effector cd8+ t\u00a0cell responses to virus infection and cancer","volume":"38","author":"Dudda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100978_bib73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cmet.2022.02.003","article-title":"Metabolic programs tailor T\u00a0cell immunity in viral infection, cancer, and aging","volume":"34","author":"M\u00f8ller","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2023.100978_bib74","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T\u00a0cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2023.100978_bib75","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","article-title":"Metabolic consequences of T-cell costimulation in anticancer immunity","volume":"7","author":"Teijeira","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.seminoncol.2015.02.009","article-title":"Immune response regulation in the tumor microenvironment by hypoxia","volume":"42","author":"Labiano","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.xcrm.2023.100978_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","article-title":"Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T\u00a0cells","volume":"21","author":"Engelhardt","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib78","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccell.2014.10.008","article-title":"CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance","volume":"26","author":"Zitvogel","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.100978_bib79","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-21-3226","article-title":"IFN\u03b3 signaling in natural and therapy-induced antitumor responses","volume":"28","author":"Mart\u00ednez-Sabadell","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.100978_bib80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-cancerbio-070220-111016","article-title":"Central role of the antigen-presentation and interferon-\u03b3 pathways in resistance to immune checkpoint blockade","volume":"6","author":"Paschen","year":"2022","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2018.04.001","article-title":"The tolerogenic role of IFN-\u03b3","volume":"41","author":"Ro\u017eman","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2023.100978_bib82","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI44952","article-title":"IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T\u00a0cells","volume":"121","author":"Fisher","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2023.100978_bib83","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T\u00a0cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2023.100978_bib84","doi-asserted-by":"crossref","first-page":"2147317","DOI":"10.1080\/2162402X.2022.2147317","article-title":"Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8\u00a0+ T\u00a0cells eradicates peritoneal metastases in mouse models","volume":"12","author":"Di Trani","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2023.100978_bib85","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1073\/pnas.1506357112","article-title":"Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb","volume":"112","author":"Weigelin","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.xcrm.2023.100978_bib86","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.100978_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.100978_bib88","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.100978_bib89","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1083\/jcb.130.4.807","article-title":"Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75","volume":"130","author":"Vijayasaradhi","year":"1995","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2023.100978_bib90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat. Methods"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:53:00Z","timestamp":1762987980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2666379123000848"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100978","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T\u00a0cells for efficacious intratumoral adoptive immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.100978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"100978"}}